Vicky Bowyer

Vicky Bowyer

Auto-generated profile, based on publicly available information

Vicky Bowyer

Department of Twin Research and Genetic Epidemiology, School of Life Course & Population Science, King’s College London, London, UK

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 July 2023 in eClinicalMedicine
Verified
Journal Article
Open access
NCNathan J. Cheetham
Nathan J. Cheetham
RPRose Penfold
Rose Penfold
VGValentina Giunchiglia
Valentina Giunchiglia
VBVicky Bowyer
Vicky Bowyer
CSCarole H. Sudre
Carole H. Sudre
CSClaire Steves
Claire Steves
Cognitive impairment has been reported after many types of infection, including SARS-CoV-2. Whether deficits following SARS-CoV-2 improve over time is unclear. Studies to date have focused on hospitalised individuals with up to a year follow-up. The presence, magnitude, persistence and correlations of effects in community-based cases remain relatively unexplored. Cognitive performance (working memory, attention, reasoning, motor control) was assessed in a prospective cohort study of participants from the United Kingdom COVID Symptom Study Biobank between July 12, 2021 and August 27, 2021 (Round 1), and between April 28, 2022 and June 21, 2022 (Round 2). Participants, recruited from the COVID Symptom Study smartphone app, comprised individuals with and without SARS-CoV-2 infection and varying symptom duration. Effects of COVID-19 exposures on cognitive accuracy and reaction time scores were estimated using multivariable ordinary least squares linear regression models weighted for inverse probability of participation, adjusting for potential confounders and mediators. The role of ongoing symptoms after COVID-19 infection was examined stratifying for self-perceived recovery. Longitudinal analysis assessed change in cognitive performance between rounds. 3335 individuals completed Round 1, of whom 1768 also completed Round 2. At Round 1, individuals with previous positive SARS-CoV-2 tests had lower cognitive accuracy (N = 1737, β = −0.14 standard deviations, SDs, 95% confidence intervals, CI: −0.21, −0.07) than negative controls. Deficits were largest for positive individuals with ≥12 weeks of symptoms (N = 495, β = −0.22 SDs, 95% CI: −0.35, −0.09). Effects were comparable to hospital presentation during illness (N = 281, β = −0.31 SDs, 95% CI: −0.44, −0.18), and 10 years age difference (60–70 years vs. 50–60 years, β = −0.21 SDs, 95% CI: −0.30, −0.13) in the whole study population. Stratification by self-reported recovery revealed that deficits were only detectable in SARS-CoV-2 positive individuals who did not feel recovered from COVID-19, whereas individuals who reported full recovery showed no deficits. Longitudinal analysis showed no evidence of cognitive change over time, suggesting that cognitive deficits for affected individuals persisted at almost 2 years since initial infection. Cognitive deficits following SARS-CoV-2 infection were detectable nearly two years post infection, and largest for individuals with longer symptom durations, ongoing symptoms, and/or more severe infection. However, no such deficits were detected in individuals who reported full recovery from COVID-19. Further work is needed to monitor and develop understanding of recovery mechanisms for those with ongoing symptoms. 10.13039/100011721 Chronic Disease Research Foundation , 10.13039/100010269 Wellcome Trust , 10.13039/501100000272 National Institute for Health and Care Research , 10.13039/501100000265 Medical Research Council , 10.13039/501100000274 British Heart Foundation , 10.13039/501100000320 Alzheimer's Society , European Union, COVID-19 Driver Relief Fund, French National Research Agency.

22 February 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
LMLaura A Magee
Laura A Magee
EMErika Molteni
Erika Molteni
VBVicky Bowyer
Vicky Bowyer
JBJeffrey N. Bone
Jeffrey N. Bone
HBHarriet Boulding
Harriet Boulding
SWSara White
Sara White
Women of reproductive age are a group of particular concern with regards to vaccine uptake, related to their unique considerations of menstruation, fertility, and pregnancy. To obtain vaccine uptake data specific to this group, we obtained vaccine surveillance data from the Office for National Statistics, linked with COVID-19 vaccination status from the National Immunisation Management Service, England, from 8 Dec 2020 to 15 Feb 2021; data from 13,128,525 such women at population-level, were clustered by age (18–29, 30–39, and 40–49 years), self-defined ethnicity (19 UK government categories), and index of multiple deprivation (IMD, geographically-defined IMD quintiles). Here we show that among women of reproductive age, older age, White ethnicity and being in the least-deprived index of multiple deprivation are each independently associated with higher vaccine uptake, for first and second doses; however, ethnicity exerts the strongest influence (and IMD the weakest). These findings should inform future vaccination public messaging and policy.

10 January 2025 in Journal of Infection
Verified
Journal Article
Open access
KRKhaled Rjoob
Khaled Rjoob
MAMichela Antonelli
Michela Antonelli
BMBenjamin Murray
Benjamin Murray
EMErika Molteni
Erika Molteni
NCNathan Cheetham
Nathan Cheetham
CSCarole H. Sudre
Carole H. Sudre
COVID-19 symptoms may persist beyond acute SARS-CoV-2 infection, as ongoing symptomatic COVID-19 [OSC] (symptom duration 4-12 weeks) and post-COVID syndrome [PCS] (symptom duration ≥12 weeks). Vaccination against SARS-CoV-2 decreases OSC/PCS in individuals subsequently infected with SARS-CoV-2 post-vaccination. Whether vaccination against SARS-CoV-2, or any other vaccinations (such as against influenza) affects symptoms in individuals already experiencing OSC/PCS, more than natural symptom evolution, is unknown. Using data from the ZOE COVID Symptom Study app, two comparative analyses were carried out, both in prospectively-reporting individuals with OSC/PCS: A) symptoms in individuals receiving first vaccination against SARS-CoV-2, compared with unvaccinated individuals, matched for age, sex, BMI and week of test (n=1679 in each group); B) symptoms in individuals receiving vaccination against influenza, compared with unvaccinated individuals, matched for age, sex, BMI, week of test and number of SARS-CoV-2 vaccinations (n=692 in each group). In both analyses, vaccination date (or equivalent time from start of symptoms in the unvaccinated group) was considered as the index time, and symptom evolution was measured by comparing symptoms during the second week before and second week after vaccination. Symptoms were considered by prevalence and burden over the considered periods; all results were adjusted for multiple comparisons. After first vaccination against SARS-CoV-2, many symptoms in individuals with OSC/PCS improved more rapidly than natural history resolution, including the commonly reported symptoms of fatigue (p<0.0001, β=--0.9 [95% CI: -1.86; -0.67]) and myalgia (p<0.001, β=-0.3 [95% CI: -0.50; -0.12]). No symptom worsened after vaccination. In contrast, there was no improvement in OSC/PCS symptoms beyond natural history resolution after vaccination against influenza. In individuals with OSC/PCS, symptom resolution improved after vaccination against SARS-CoV-2 ; this was not observed, however, after other vaccinations.

24 February 2026 in BMC Medicine
Verified
Journal Article
Open access
Sergio A. SilverioSergio A. Silverio
Sergio A. Silverio
JBJulia R. B. Brown
Julia R. B. Brown
VBVicky Bowyer
Vicky Bowyer
CSCarole H. Sudre
Carole H. Sudre
GHGillian Horgan
Gillian Horgan
EDEmma L. Duncan
Emma L. Duncan
Background Good quality postnatal care is of key importance for maternal and infant health. During the pandemic, healthcare services were reconfigured with increased virtual delivery, reducing infection transmission risk for pregnant women, new mothers, newborn babies, and healthcare workers. Post-pandemic, this shift of maternity care from faceto-face towards virtual care provision has persisted. Whilst some have extolled this trend, the evidence is mixed, both for clinical outcomes and for patient perceptions and experiences. We sought to explore the experiences and perceptions of women affected by these changes, to inform ongoing maternity services development. Methods This study reports responses of women participating in the COVID Symptom Study Biobank, drawn from the King's College London/ZOE COVID Symptom Study, representing a convenience sample of UK women of reproductive age (18-50 years). Participants were invited to complete an online questionnaire, from 7 September to 1 December 2021. Demographic analyses are presented for all respondents. Content analysis was used to analyse all free-text responses. Results Overall, 1036 respondents delivered at least one live baby during the pandemic, of whom 821 respondents provided a total of 1466 qualitative responses about their care in-person (n = 550 responses), by video (n = 125), or by telephone (n = 791). Mothers liked the convenience and promptness of virtual care, and generally felt it was a good way to meet their healthcare needs, with two caveats: First, they appreciated the option to escalate care quickly (i.e. a tiered process), which seemed to occur with little difficulty in most cases; second, they perceived physical examination as very important in certain circumstances, particularly when a baby was unwell. Conclusions Our findings show women are pragmatic and reasonable about the benefits and risks of differing modes of postpartum care delivery, including virtual care. Our study supports a tiered approach to the provision of postnatal care, which balances perceived efficiencies, preferences of the individual seeking care, and level of clinical concern.

13 September 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
LMLaura A Magee
Laura A Magee
EMErika Molteni
Erika Molteni
VBVicky Bowyer
Vicky Bowyer
JBJeffrey N. Bone
Jeffrey N. Bone
HBHarriet Boulding
Harriet Boulding
SWSara White
Sara White